AIDS Research and Therapy 2015, 12:12 (24 April 2015)
This study consists of a descriptive analysis of M. tuberculosis isolates from Beira Central Hospital, Mozambique, during 2014–2015, being the first report of a genotypic testing used to provide information about second line drug resistance in Mozambique.
BMC Infectious Diseases (2016) 16:423 DO...I 10.1186/s12879-016-1766-x
more
[Updated 2015]
Scoping Question: In adults with acute convulsive seizures in first-level care or in the community (when no IV access is available), which antiepileptic medications produce benefits and/or harm when compared to comparator?
SCOPING QUESTION: In adults with established status epilepticus (i.e., seizures persisting after the first-line treatment with benzodiazepines [or benzodiazepines-resistant status epilepticus]), which anti-epileptic medications are associated with cessation of seizures and reduced adverse effects)?
...
more
African Health Sciences 2013; 13(2): 219 - 232 http://dx.doi.org/10.4314/ahs.v13i2.4
BMC Public Health (2016) 16:766
DOI 10.1186/s12889-016-3455-5
Módulo 1
Clínico
Julho de 2017
Módulo 1: Clínico. Este módulo é destinado a profissionais de saúde como médicos, enfermeiros e auxiliares e traz um resumo sobre como prover a PrEP de forma segura e efetiva, abordando vários aspectos: triagem de pessoas com risco substancial de contr...air o HIV;
ódulo 1: Clínico. Este módulo é destinado a profissionais de saúde como médicos, enfermeiros e auxiliares e traz um resumo sobre como prover a PrEP de forma segura e efetiva, abordando vários aspectos: triagem de pessoas com risco substancial de contrair o HIV; testagem de HIV antes de iniciar a PrEP e como acompanhar usuários de PrEP e oferecer aconselhamento sobre adesão.
more
Version 2, updated 17 March 2016
The international community sits at the tipping pointof a post-‐antibiotic era, where common bacterial infections are no longer treatable with the antibiotic armamentarium that exists. In South Africa, t...he identification of the first case of pan-‐resistant Klebsiella pneumoniae(Brink et al, J Clin Microbiol. 2013;51(1):369-‐72) marks a watershed moment and highlights ourtip of the antibiotic resistance ‘iceberg’ in this country. Multi-‐drug resistant (MDR)-‐bacterial infections, predominantly in Gram-‐negative bacteria such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosaand Acinetobacter baumanniiare now commonplace in South African hospitals. Whilst a number of expensive new antibiotics for Gram-‐positive bacterial infections have been manufactured recently (some of which are licenced for usein South Africa), no new antibiotics active against Gram-‐negative infections are expected in the next 10-‐15years. Hence what we have now, needs conserving
more